pfizer glp-1 news scraps daily weight loss pill danuglipron after a liver injury Regor notches minor victory in

Encouragingly, there may now be a better solution than any of these three hacks. Novo Nordisks Wegovy pill, an oral form of semaglutide, was FDA-approved in December 2025 and launched in January 2026

GLP-1 agonist to treat obesity and prevent cardiovascular disease: What have we achieved so far

A three-year obesity and prediabetes trial found that LIR 3 mg can improve health benefits in reducing the diabetes risk of patients with obesity and prediabetes (91)

But it wasnt until semaglutide hit the market (first as Ozempic [archived link] in 2017 followed by Wegovy [archived link]) in 2021) that GLP-1 RAs captured the worlds attention

found that 52 weeks of once-weekly semaglutide (the active ingredient in Ozempic and Wegovy) reduced hip bone mineral density by 2.6% and lumbar spine density by 2.1% compared to placebo in adults with increased fracture risk

Trial data show comparable rates of nausea, vomiting, and diarrhea to the injectable